Clinical Trials
46 trialsTesting the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
SEAMARK
Pfizer
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
SWOG Cancer Research Network
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
COCHISE
Institut Bergonié
MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
TheraOp
CRIT
Sixth Affiliated Hospital, Sun Yat-sen University
TORCH-R
Fudan University
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
Eastern Cooperative Oncology Group
Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer
Medical Research Council
MK-0646-025
Merck Sharp & Dohme LLC
Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma
Abramson Cancer Center at Penn Medicine
Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery
UNICANCER
Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum
University of Wisconsin, Madison
Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis
Korea Cancer Center Hospital
Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
Dana-Farber Cancer Institute
FC-4
Eli Lilly and Company
S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer
SWOG Cancer Research Network
Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer
RenJi Hospital
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
National Institutes of Health Clinical Center (CC)
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
Alliance for Clinical Trials in Oncology
Pre-op Rectal ChemoRad +/- Cetuximab
US Oncology Research
Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy
University of Pittsburgh
Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer
Alliance for Clinical Trials in Oncology
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
National Cancer Institute (NCI)
Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment
City of Hope Medical Center
A Study of Radiotherapy in Rectal Cancer Using Oxaliplatin, Capecitabine With or Without Cetuximab
National University Hospital, Singapore
Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery
Duke University
Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer
University of Alabama at Birmingham
Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery
Vanderbilt-Ingram Cancer Center
ERBIFORT
National Cancer Institute, France
Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
Swiss Cancer Institute
XERT
Institute of Oncology Ljubljana
Preoperative Chemoradiation With Capecitabine and Cetuximab
Austrian Breast & Colorectal Cancer Study Group
Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Cetuximab and Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
EXPERT-C
Royal Marsden NHS Foundation Trust
Cetuximab in Treating Patients With Stage IV Colorectal Cancer
National Cancer Institute (NCI)
Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients
Copenhagen University Hospital at Herlev
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
National Cancer Institute (NCI)
ERBIRIX
National Cancer Center, Korea